Trending Topics


Check out the latest cancer-related news and also see who is readily available to offer reliable information, expert commentary, and reaction to today's headlines.
Contact a media coordinator

Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical trials published in the New England Journal of Medicine. The landmark data support the foundation of precision oncology by creating a treatment option for a genetically defined cancer while continuing to validate the concept that comprehensive molecular profiling should be strongly considered in people of all ages with advanced solid tumors.
Wednesday, February 21, 2018
MSK’s Neil Iyengar will present at the American Association for Cancer Research special conference about the risk of invasive breast cancer. A new study found that the risk of invasive breast cancer is increased in postmenopausal women with a normal body mass index (BMI) but higher levels of body fat. These findings suggest that having a normal BMI can provide false reassurance regarding the risk of breast cancer associated with body fat, and they also highlight the potential role of physical activity and exercise even in those who are at a normal weight. For expert interviews, please contact Nicole H. McNamara at
Friday, January 26, 2018
A new study from Memorial Sloan Kettering’s (MSK) Marcel van den Brink— in collaboration with Jarrod Dudakov, PhD, at the Fred Hutchinson Cancer Center — has identified a molecule that promotes thymus regeneration. The results could pave the way toward treatments that could one day help rejuvenate an aging or damaged thymus. For more information or to speak with an expert, contact Rebecca Williams at
Friday, January 12, 2018
See all trending topics

Press Releases

Researchers at Memorial Sloan Kettering (MSK) report today in the New England Journal of Medicine that adult patients with acute lymphoblastic leukemia (ALL) who received chimeric antigen receptor (CAR) T cell therapy responded better if they had a small amount of disease at the time of the treatment. Compared with patients with a greater amount of disease, those in the low-disease category lived significantly longer and experienced fewer life-threatening side effects.  
Wednesday, January 31, 2018
Two projects from a portfolio of 57 that the Tri-I TDI has supported have “graduated” with the demonstration that the compounds under study work in preclinical contexts. These compounds are now ready for the next phase of therapeutic development – a phase intended to lead to investigational new drugs. A third project, which originated at Weill Cornell Medicine, is expected to move forward later this month. These projects are candidates for advancement into Bridge Medicines, Inc., a for-profit company established in 2016 by the three Tri-I TDI academic founders, Takeda, and two investment firms – Bay City Capital and Deerfield Management – designed to take Tri-I TDI projects into readiness for clinical trials over a two- to three-year time frame.
Monday, January 22, 2018
Viviane Tabar, MD, has been named the new Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Tabar has been a vital faculty member at MSK for more than 15 years and is currently the Theresa C. Feng Chair for Neurosurgical Oncology and the Vice Chair for Neurosurgical Research and Education.
Wednesday, December 6, 2017
See all press releases

On Our Blog

Learn about a hospital-wide program that empowers children before they undergo surgery at Memorial Sloan Kettering.
Friday, March 16, 2018
Learn about the different options for colorectal cancer screening and why MSK experts believe that screening is so important.
Thursday, March 15, 2018
Learn how people with cancer can reduce insomnia during and after treatment.
Thursday, March 15, 2018
See all blog posts

Media Coverage

Families that discover a mutation of the CDH1 gene find preventive removal of the stomach a harsh but necessary step. MSK’s Vivian Strong, Kenneth Offit and MSK patients are featured. 
Tuesday, March 6, 2018
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor, had “marked and durable antitumor activity” in both children and adults with TRK-fusion positive cancer, regardless of the tumor type. MSK senior study author David Hyman is highlighted.
Tuesday, February 27, 2018
Health care startup Paige.AI, founded by MSK’s Thomas Fuchs and co-founder David Klimstra, announced it has raised $25 million to continue its work in cancer diagnosis with help from computer vision trained with clinical imaging data. Initial work will center on the detection of breast, prostate, and other major cancers. Paige.AI has signed an agreement with Memorial Sloan Kettering Cancer Center to gain access to its database of 25 million pathology slides.
Tuesday, February 6, 2018
See all media coverage

If you wish to contact MSK about a marketing or advertising related opportunity, or are looking for additional information about our ad campaign, please email us at

For Journalists

Jeanne D'Agostino
Director, Media and Public Relations
Emily O'Donnell
Media Relations Manager, Surgery
Courtney Nowak
Media Relations Manager, Regional Care Network
Caitlin Hool
Senior Manager, Media Relations and Partnerships
Nicole H. McNamara
Senior Media Strategist
Rebecca Williams
Media Strategist
For press inquiries, our Media Staff are available by calling 646-227-3573 or by dialing the numbers above. Our office hours are Monday - Friday, 9:00 AM to 5:00 PM.
After hours, please contact the hospital's page operator at 212-639-7900 and ask for the Public Affairs representative on-call.

Live and Remote Broadcast Capabilities

Our experts can offer live broadcast interviews using the on-site studio system. To book an expert interview using our on-site broadcast studio contact our Media Staff.